PharmaCyte Biotech, Inc. Common Stock (PMCB) Stock Price

PMCBStock

$0.34−65.11%52W

Market Cap$3.65M

P/E0.20x

PEG Ratio—

Div yield—

Beta0.75

PMCB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-60.17%

Price vs S&P 500 (4W)-23.21%

VGM Score26.96

P/E Ratio (Annual)0.20x

Book Value / Share (Quarterly)$2.78

P/TBV (Annual)0.22x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)-64.94%

Gross Margin (TTM)81.70%

Net Profit Margin (TTM)-4184.21%

EPS (TTM)$-1.90

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-1.90

EPS (Annual)$-2.32

ROI (Annual)-55.53%

Gross Margin (Annual)0.00%

Net Profit Margin (5Y Avg)-4635.63%

Cash / Share (Quarterly)$2.84

P/E Normalized (Annual)0.20x

ROA (Last FY)-41.55%

EBITD / Share (TTM)$-0.75

ROE (5Y Avg)-1.25%

Operating Margin (TTM)-3469.42%

Cash Flow / Share (Annual)$-0.48

P/B Ratio0.12x

P/B Ratio (Quarterly)0.21x

Net Income / Employee (Annual)$-9,712,300

EV / Revenue (TTM)-353.05x

Net Interest Coverage (TTM)-4.34x

ROA (TTM)-33.07%

EV / EBITDA (TTM)-6.47x

EPS Incl Extra (Annual)$-2.32

Current Ratio (Annual)45.28x

Quick Ratio (Quarterly)40.25x

3-Month Avg Trading Volume0.17M

52-Week Price Return-65.11%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.26

P/S Ratio (Annual)365.23x

Asset Turnover (Annual)0.00x

52-Week High$1.51

Operating Margin (5Y Avg)-4103.67%

EPS Excl Extra (Annual)$-2.32

Tangible BV CAGR (5Y)62.05%

26-Week Price Return-50.26%

Quick Ratio (Annual)45.16x

13-Week Price Return-46.26%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)40.30x

Enterprise Value$-14.09M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-4.96%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.33x

Pretax Margin (Annual)-16000.00%

Cash / Share (Annual)$3.45

3-Month Return Std Dev60.29%

Gross Margin (5Y Avg)37.52%

Net Income / Employee (TTM)$-8,072,900

ROE (Last FY)-55.53%

Net Interest Coverage (Annual)-0.03x

EPS Basic Excl Extra (Annual)$-2.32

Receivables Turnover (TTM)1.96x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.90

Receivables Turnover (Annual)26.00x

ROI (TTM)-45.88%

P/S Ratio (TTM)91.54x

Pretax Margin (5Y Avg)-4635.63%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.26

Price vs S&P 500 (52W)-80.64%

Year-to-Date Return-53.01%

5-Day Price Return-6.82%

EPS Normalized (Annual)$-2.32

ROA (5Y Avg)0.80%

Net Profit Margin (Annual)-16000.00%

Month-to-Date Return-17.15%

Cash Flow / Share (TTM)$-0.21

EBITD / Share (Annual)$-0.81

Operating Margin (Annual)-14500.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-1.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.90

P/TBV (Quarterly)0.22x

P/B Ratio (Annual)0.22x

Inventory Turnover (TTM)5.10x

Pretax Margin (TTM)-4184.21%

Book Value / Share (Annual)$3.26

Price vs S&P 500 (13W)-48.94%

Beta0.75x

Revenue / Share (TTM)$0.00

ROE (TTM)-45.88%

52-Week Low$0.33

mGradeD

vgmGradeD

PMCB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2022	Sep 14, 2022	-$0.07	-$0.07	+0.00%(+$0.00)
Q1 2022	Jul 28, 2022	-$0.04	-$0.06	-50.00%(-$0.02)
Q4 2021	Mar 15, 2022	-$0.05	-$0.04	+20.00%(+$0.01)
Q3 2021	Dec 14, 2021	-$0.07	-$0.06	+14.29%(+$0.01)

PMCB Analyst Recommendations

Nov 2022

Dec 2022

Jan 2023

Feb 2023

2.17

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PMCBPharmaCyte Biotech, Inc. Common Stock	—	—	D	91.5x	—	81.7%	—	$0.34
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About PharmaCyte Biotech, Inc. Common Stock

PharmaCyte Biotech is a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology, which encapsulates live cells to deliver cancer-killing drugs directly at tumor sites. The platform is designed to protect therapeutic cells from the immune system while enabling localized drug delivery, with current development efforts focused on inoperable pancreatic cancer and other solid tumors. The company is leveraging this platform technology to address multiple cancer indications and diabetes.